A new diagnostic development in MRI screening for breast cancer
- Conditions
- 10006291breast cancermamma carcinoma
- Registration Number
- NL-OMON33969
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
solid breast lesion >= 1cm
BIRADS classification 3 or 4 on the mammogram.
Patients are >= 18 years
Exclusion Criteria
history of breast cancer
breast hematoma
protheses
claustrophobia
non-MR compatible implants
disorder of kidney function
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>To compare the specificity of the multiple-voxel MR spectroscopy with the<br /><br>standard MRI and<br /><br>as second main aim a reduction of the number of false-positive diagnostic<br /><br>outcomes.<br /><br>Sensitivity, specificity, positive predictive value, negative predictive value<br /><br>and 95% CI will be calculated. </p><br>
- Secondary Outcome Measures
Name Time Method <p>No applicable</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does CSI technology target in breast cancer MRI diagnostics?
How does CSI MRI compare to standard-of-care imaging techniques in breast cancer detection?
What biomarkers are associated with improved outcomes in breast cancer MRI screening using CSI?
Are there specific adverse events linked to CSI MRI in breast cancer patients and how are they managed?
What are the potential applications of CSI MRI in combination with other breast cancer diagnostic modalities?